Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Cibus Global LLC

Healthcare US CBUS

1.3USD
-0.06(4.41%)

Last update at 2026-06-22T20:00:00Z

Day Range

1.271.45
LowHigh

52 Week Range

1.094.19
LowHigh

Fundamentals

  • Previous Close 1.36
  • Market Cap120.58M
  • Volume300452
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-61.54100M
  • Revenue TTM3.64M
  • Revenue Per Share TTM0.08
  • Gross Profit TTM 3.64M
  • Diluted EPS TTM-2.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -132.17200M -282.68400M -337.64300M -16.89100M -29.19900M
Minority interest 5.12M 31.32M 70.01M - -
Net income -127.08500M -251.38800M -267.62700M -16.89100M -29.19900M
Selling general administrative 26.91M 30.80M 23.14M 10.97M 15.38M
Selling and marketing expenses - - - - -
Gross profit -2.28400M 4.26M 1.42M 0.16M -2.57000M
Reconciled depreciation 5.92M 6.86M 3.25M 1.53M 2.34M
Ebit -67.46400M -248.49400M -319.27800M -23.90400M -30.86000M
Ebitda -61.54100M -241.63500M -314.58500M -22.37000M -28.52200M
Depreciation and amortization 5.92M 6.86M 4.69M 1.53M 2.34M
Non operating income net other - - - - -
Operating income -67.46400M -258.39600M -318.88300M -22.37000M -29.33200M
Other operating expenses 71.10M 262.66M 320.70M 22.53M 55.32M
Interest expense 35.48M 34.19M 18.89M 0.07M 1.43M
Tax provision 0.03M 0.03M -0.00400M 0.00000M 0.00000M
Interest income 0.44M 0.63M 0.53M 0.06M 0.02M
Net interest income -35.04300M -33.55900M -10.40100M -0.08700M -1.41400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.03M 0.03M -0.00400M -1.44700M -0.11400M
Total revenue 3.64M 4.26M 1.82M 0.16M 25.99M
Total operating expenses 65.18M 262.66M 320.31M 22.53M 26.76M
Cost of revenue 5.92M 6.86M 0.40M 0.00000M 28.56M
Total other income expense net -64.70800M -24.28800M -18.76000M 5.57M 1.55M
Discontinued operations - - - - -
Net income from continuing ops -132.20100M -282.71300M -63.26800M -16.89100M -29.19900M
Net income applicable to common shares - - - -16.89100M -29.19900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 305.05M 350.07M 544.41M 22.42M 37.19M
Intangible assets 31.68M 33.58M 35.41M - -
Earning assets - - - - -
Other current assets 1.44M 1.47M 1.99M 0.61M 0.86M
Total liab 283.22M 252.24M 206.12M 15.19M 23.06M
Total stockholder equity 21.83M 97.83M 293.47M 7.23M 14.13M
Deferred long term liab - - - - -
Other current liab 5.09M 8.15M 7.04M 1.23M 3.22M
Common stock 0.08M 0.00900M 0.00800M 0.00500M 0.00400M
Capital stock 0.01M 0.00900M 0.00800M 0.00500M 0.00400M
Retained earnings -858.25100M -731.16600M -479.77800M -212.15100M -196.09200M
Other liab - - - 0.08M 0.70M
Good will 232.52M 253.47M 434.90M - -
Other assets - - - 0.16M 0.28M
Cash 9.92M 14.43M 32.70M 3.43M 13.82M
Cash and equivalents - - - - -
Total current liabilities 16.86M 19.88M 21.32M 1.66M 4.85M
Current deferred revenue 0.54M 0.93M 1.21M 0.46M 3.03M
Net debt 258.04M 21.85M -8.07800M 10.12M 4.05M
Short term debt 3.17M 0.44M 6.95M 0.10M 0.37M
Short long term debt 0.43M 0.44M 0.83M - -
Short long term debt total 267.96M 36.29M 24.62M 13.54M 17.88M
Other stockholder equity 880.03M 823.30M 771.82M 219.38M 210.22M
Property plant equipment - - - 18.13M 21.73M
Total current assets 12.07M 16.95M 35.22M 4.13M 15.18M
Long term investments - - - - -
Net tangible assets - - - 7.23M 14.13M
Short term investments - - - - 0.00000M
Net receivables 0.70M 1.04M 0.53M - 0.00000M
Long term debt 0.09M 0.23M 0.54M - -
Inventory - - - - 0.00000M
Accounts payable 8.07M 5.96M 6.13M 0.34M 1.26M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.04M 0.01M 0.00800M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.93M 1.39M 1.42M 0.16M 0.28M
Deferred long term asset charges - - - - -
Non current assets total 292.98M 333.12M 509.19M 18.29M 22.01M
Capital lease obligations 32.51M 35.62M 23.25M 13.54M 17.88M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.80800M 55.50M -1.52000M 11.20M
Change to liabilities - - - -0.22900M -0.36000M
Total cashflows from investing activities -0.57800M -0.80800M 55.06M -1.52000M 11.20M
Net borrowings -1.10800M -0.87900M 2.31M -0.37600M -0.36400M
Total cash from financing activities 46.65M 40.60M 20.32M 9.99M 3.74M
Change to operating activities - - - -2.65600M 1.58M
Net income -127.08500M -282.71300M -267.62700M -16.89100M -29.19900M
Change in cash -4.51000M -18.26600M 29.17M -10.89500M -3.86800M
Begin period cash flow 14.43M 32.70M 3.53M 14.42M 18.29M
End period cash flow 9.92M 14.43M 32.70M 3.53M 14.42M
Total cash from operating activities -50.59100M -58.04300M -46.21000M -19.36400M -18.81100M
Issuance of capital stock 50.10M 43.90M 0.33M 11.54M 4.38M
Depreciation 5.92M 6.86M 4.69M 1.53M 2.34M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - -0.91500M 0.00000M 1.38M
Change to account receivables 0.54M -0.51200M 1.70M 0.00000M 4.89M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.14200M -2.42500M 1.76M -1.17300M -0.27400M
Change to netincome - - - -1.12200M 0.56M
Capital expenditures 0.58M 0.81M 4.32M 1.52M 0.50M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.32M 0.38M 0.96M -2.88500M 7.49M
Stock based compensation 8.19M 10.75M 16.09M 4.00M 2.09M
Other non cash items 60.06M 206.68M 215.76M -5.12000M -1.52800M
Free cash flow -51.16900M -58.85100M -50.53100M -20.88400M -19.30800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CBUS
Cibus Global LLC		 -0.06 4.41% 1.30 - - 33.14 5.46 39.11 -1.1479
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

Cibus Global LLC

6455 Nancy Ridge Drive, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Rory Balfour Riggs M.B.A. Co-Founder, CEO & Chairman 1953
Dr. Peter Beetham B.Sc., Ph.D. Co-Founder, President, COO & Director 1963
Dr. Greg Gocal Ph.D. Co-Founder, Chief Scientific Officer & Executive VP 1969
Dr. Wade Hampton King Chief Financial Officer 1958
Mr. Jason Stokes J.D. Chief Legal Officer, General Counsel & Corporate Secretary NA
Ms. Rosa Cheuk Kim J.D. Senior Vice President of Legal NA
Dr. James Radtke Ph.D. Senior Vice President of Product Development NA
Mr. Tony Moran Senior Vice President of International Development NA
Norm Sissons Senior Vice President of Seed & Traits NA
Ms. Noel Sauer Ph.D. Senior Vice President of Research NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions